Fa'amatalaga atili ― Samoan

Urticarial vasculitis ose ma'i e seasea fa'ailogaina i fa'ama'i umi po'o fa'atupu fa'afuase'i. E ui o ona fa'a'ailoga o le pa'u e mafai ona pei o fa'ama'i faaumiumi, ae e tulaga ese lava ona e pipii solo ia fa'ama'i mo le itiiti ifo i le 24 itula ma e mafai ona fa'apouliuligia pe a mou atu. E ui lava e masani ona le iloa le mafuaʻaga, e mafai i nisi taimi ona faʻaosoina e nisi o vailaʻau, faʻamaʻi pipisi, faʻamaʻi autoimmune, faʻamaʻi toto, poʻo kanesa. O nisi suʻesuʻega ua faʻafesoʻotaʻi i le COVID-19 ma le H1N1 flu. E mafai foi ona aafia ai isi vaega o le tino e pei o maso, fatuga'o, mama, manava, ma mata. E ui o se ituaiga o su'esu'ega a le tino e mafai ona fa'amaonia le su'esu'ega, e le o taimi uma e mana'omia ai. Togafitiga masani e amata ile antibiotic, dapsone, colchicine, po'o le hydroxychloroquine mo ma'i vaivai. Mo tulaga ogaoga, e ono mana'omia ni vaila'au e taofia ai le puipuiga e pei o le methotrexate po'o corticosteroids. Talu ai nei, o togafitiga faʻaola (rituximab, omalizumab, interleukin-1 inhibitors) ua faʻaalia le folafolaga mo mataupu faigata.
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.

O se alii e 35-tausaga le matua na sau i totonu ma le 15-aso talafaasolopito o mumu sesega, mageso tiga i luga uma o ogavae ma vae, faatasi ai ma le tiga o sooga. Na maua o ia i le ma'i o le urinary tract mo le vaiaso a'o le'i aliali mai le mageso. O lona pa'u na fa'aalia ai le tele o ma'ale'ale, fa'amama mama, o se vaega e pa'epa'e, lanu mumu i itu uma e lua o ona ogavae ma vae. Na tuʻuina atu ia te ia le prednisolone tautala (40mg / aso) mo le vaiaso faʻatasi ai ma se antihistamine e le moe (fexofenadine) . I totonu o le vaiaso, na mou atu uma mageso uma. Ua le toe iai se mageso i le isi 6 masina o siaki masani.
A 35-year-old man came in with a 15-day history of bright red, painful rashes on both thighs and legs, along with joint pain. He had a urinary tract infection for a week before the rash appeared. His skin showed several tender, ring-shaped, partially blanchable, red plaques on both sides of his thighs and legs. He was given oral prednisolone (40mg/day) for a week along with a non-drowsy antihistamine (fexofenadine). Within a week, all the rashes disappeared completely. There were no more rashes during the next 6 months of regular check-ups.